Literature DB >> 26299611

Pulmonary hypertension due to left heart disease: The prognostic implications of diastolic pulmonary vascular pressure gradient.

Tatsuro Ibe1, Hiroshi Wada2, Kenichi Sakakura1, Nahoko Ikeda1, Yoko Yamada1, Yoshitaka Sugawara1, Takeshi Mitsuhashi1, Junya Ako1, Hideo Fujita1, Shin-Ichi Momomura1.   

Abstract

BACKGROUND: Compared to transpulmonary pressure gradient (TPPG), diastolic pulmonary vascular pressure gradient (DPG) may be a more sensitive and specific indicator for pulmonary hypertension (PH) due to left heart disease (LHD) with significant pulmonary vascular disease (PVD). The aim of this study was to investigate the incidence and clinical features of PH-LHD with PVD classified by DPG and TPPG.
METHODS: We analyzed 410 patients admitted for symptomatic heart failure (HF) (New York Heart Association ≥2) and who underwent right heart catheterization (RHC) at compensated stage between 2007 and 2012. Patients with PH-LHD were divided into 3 groups according to the value of DPG and TPPG (Non-PVD group: DPG <7mmHg and TPPG ≤12mmHg; TPPG-PVD group: DPG <7mmHg and TPPG >12mmHg; DPG-PVD group: DPG ≥7mmHg). Multivariate Cox regression analysis was applied to investigate whether each PH-LHD category predicts death or HF readmission after adjusting for other variables.
RESULTS: PH-LHD was observed in 164 patients (40%) with symptomatic HF. Thirteen patients (3%) were allocated into DPG-PVD group, while 24 patients were allocated into TPPG-PVD group (6%). DPG-PVD group was significantly associated with death or HF readmission compared to non-PVD group (hazard ratio: 3.57; 95% CI: 1.33 to 9.55, p=0.01), while the association between TPPG-PVD group and non-PVD group did not reach statistical significance (hazard ratio: 1.89; 95% CI: 0.77 to 4.64, p=0.17).
CONCLUSIONS: PH-LHD with PVD classified by DPG was significantly associated with poor long-term clinical outcomes, whereas the association between PH-LHD with PVD classified by TPPG and clinical outcomes did not reach statistical significance. However, further studies are needed, because there was no substantial difference in clinical outcomes between PH-LHD with PVD classified by DPG and PH-LHD with PVD classified by TPPG.
Copyright © 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diastolic pulmonary vascular pressure gradient; Heart failure; Pulmonary hypertension; Pulmonary hypertension due to left heart disease; Transpulmonary pressure gradient

Mesh:

Year:  2015        PMID: 26299611     DOI: 10.1016/j.jjcc.2015.07.015

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  5 in total

1.  Combined Post- and Precapillary Pulmonary Hypertension in Patients With Heart Failure.

Authors:  Michael E Rezaee; Elizabeth L Nichols; Mandeep Sidhu; Jeremiah R Brown
Journal:  Clin Cardiol       Date:  2016-10-21       Impact factor: 2.882

Review 2.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Authors:  Yen-Chun Lai; Longfei Wang; Mark T Gladwin
Journal:  J Physiol       Date:  2018-12-30       Impact factor: 5.182

3.  Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization.

Authors:  Michele Correale; Ilenia Monaco; Armando Ferraretti; Lucia Tricarico; Monica Sicuranza; Anna Maria Gallotta; Ennio Sascia Formica; Gianfranco Acanfora; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Int J Cardiol Heart Vasc       Date:  2020-04-21

4.  Risk prediction in pulmonary hypertension due to chronic heart failure: incremental prognostic value of pulmonary hemodynamics.

Authors:  Ruilin Quan; Shian Huang; Lingpin Pang; Jieyan Shen; Weifeng Wu; Fangming Tang; Xiulong Zhu; Weiqing Su; Jingzhi Sun; Zaixin Yu; Lemin Wang; Xianyang Zhu; Changming Xiong; Jianguo He
Journal:  BMC Cardiovasc Disord       Date:  2022-02-16       Impact factor: 2.298

Review 5.  Animal models of pulmonary hypertension due to left heart disease.

Authors:  Shao-Fei Liu; Yi Yan
Journal:  Animal Model Exp Med       Date:  2022-02-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.